1370 SAFETY AND EFFICACY OF TADALAFIL 5MG DOSED ONCE DAILY IN PATIENTS ON α-BLOCKER THERAPY FOR BENIGN PROSTATIC HYPERPLASIA ACCOMPANIED BY ERECTILE DYSFUNCTION

Field: Medicine (Health Sciences)

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy I1 Apr 20101370 SAFETY AND EFFICACY OF TADALAFIL 5MG DOSED ONCE DAILY IN PATIENTS ON α-BLOCKER THERAPY FOR BENIGN PROSTATIC HYPERPLASIA ACCOMPANIED BY ERECTILE DYSFUNCTION Joo Yong Lee, Seung Wook Lee, Tchun Yong Lee, Hae Young Park, Hong Yong Choi, Tag Keun Yoo, Hong Sang Moon, Tae Yung Jeong, Sung Yul Park, Seung Hwan Lee, Cheol Young Oh, and Jin Sung Park Joo Yong LeeJoo Yong Lee Seoul, Republic of Korea More articles by this author , Seung Wook LeeSeung Wook Lee Seoul, Republic of Korea More articles by this author , Tchun Yong LeeTchun Yong Lee Seoul, Republic of Korea More articles by this author , Hae Young ParkHae Young Park Seoul, Republic of Korea More articles by this author , Hong Yong ChoiHong Yong Choi Seoul, Republic of Korea More articles by this author , Tag Keun YooTag Keun Yoo Seoul, Republic of Korea More articles by this author , Hong Sang MoonHong Sang Moon Seoul, Republic of Korea More articles by this author , Tae Yung JeongTae Yung Jeong Goyang, Republic of Korea More articles by this author , Sung Yul ParkSung Yul Park Seoul, Republic of Korea More articles by this author , Seung Hwan LeeSeung Hwan Lee Seoul, Republic of Korea More articles by this author , Cheol Young OhCheol Young Oh Chuncheon, Republic of Korea More articles by this author , and Jin Sung ParkJin Sung Park Seoul, Republic of Korea More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.999AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES This study was conducted to evaluate the safety in the cardiovascular system, improvement in lower urinary tract symptom and restoration of sexual function when tadalafil 5mg dosed once daily was administered to patients with benign prostatic hyperplasia (BPH) who were on α-blocker therapy. METHODS This prospective study included a total of 90 BPH patients who were on 3-month or more medication of α-blockers and were additionally administered tadalafil 5mg dosed once daily. Before the administration of tadalafil (V1), blood pressure, heart rate, IPSS, Qmax, PVR and IIEF-5 were measured. Four (V2) and twelve weeks (V3) after the administration of tadalafil, blood pressure and heart rate were measured again, adverse effects of tadalafil were assessed, and sexual function and voiding symptoms were re-evaluated. RESULTS Of the 90 patients, 76 were followed up once or more, and 54 completed the 12-week clinical trial. Adverse effects were reported by 14 patients (18.4%) at V2 and by 10 patients (13.2%) at V3. Facial flushing was most commonly observed (10 patients; 6 patients [7.9%] at V2 and 4 patients [5.3%]), followed by headache (8 patients; 4 patients at V2 and 4 patients [5.3%] at V3) and dizziness (6 patients; 4 patients [5.3%] and 2 patient [2.6%]). There was no dropout due to adverse effects. Blood pressure was 139.8/88.6 mmHg at V1, 138.5/86.2 mmHg at V2 and 136.1/80.4 mmHg at V3, but the differences were not statistically significant (p=0.4 between the values at V1 and V2, p=0.3 between the values at V1 and V3). The mean heart rate was 77.2/min at V1, 78.4/min at V2 and 80.2/min at V3, but the differences were not statistically significant. IIEF-5 was 11.2 at V1, 13.5 at V2 and 15.3 at V3, and the differences were statistically significant (p=0.05 between the values at V1 and V2, p=0.002 between the values at V1 and V3. IPSS, Qmax and PVR were 17.3, 14.2 and 11.6, respectively, at V1; 10.1, 13.7 and 15.5 mL/s, respectively at V2; and 56.3, 36.2 and 29.7 mL, respectively, at V3. These differences were statistically significant (p=0.01 for IPSS, p=0.04 for Qmax and p=0.03 for PVR). CONCLUSIONS The results of this study suggest that the administration of tadalafil 5mg dosed once daily may induce few adverse effects on the cardiovascular system and may have acceptable efficacy in improving lower urinary tract symptom and restore sexual function. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e529 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joo Yong Lee Seoul, Republic of Korea More articles by this author Seung Wook Lee Seoul, Republic of Korea More articles by this author Tchun Yong Lee Seoul, Republic of Korea More articles by this author Hae Young Park Seoul, Republic of Korea More articles by this author Hong Yong Choi Seoul, Republic of Korea More articles by this author Tag Keun Yoo Seoul, Republic of Korea More articles by this author Hong Sang Moon Seoul, Republic of Korea More articles by this author Tae Yung Jeong Goyang, Republic of Korea More articles by this author Sung Yul Park Seoul, Republic of Korea More articles by this author Seung Hwan Lee Seoul, Republic of Korea More articles by this author Cheol Young Oh Chuncheon, Republic of Korea More articles by this author Jin Sung Park Seoul, Republic of Korea More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...